JK-07 (SalubrisBio)

N/A

Report date: 2026/05/16 20:00:17

Base Information

Drug NameJK-07 (SalubrisBio)
Drug Alias Name重组人神经调节蛋白 1-抗 HER3 抗体融合蛋白注射液 (信立泰)Recombinant Human Neuromodulin 1-Anti-HER3 Antibody Fusion Protein (Salubris)SAL-007SAL007JK07
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonists
TargetsReceptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsHeart Failure, SystolicHeart Failure, DiastolicHeart Failure +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPuerto Rico +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSalubris Biotherapeutics Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSalubris Biotherapeutics IncCangene Biopharma LlcSuzhou Genemen Biotech Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsHeart Failure, SystolicHeart Failure, DiastolicHeart Failure
Inactive IndicationsPulmonary Arterial Hypertension

Other Information

ATC CodeN/A
Related LinksN/A